ON 01910: all 36 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 InhibitorsTerminatedNCT05764395Phase 2Results posted
• Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and AnemiaTerminatedNCT02730884Phase 2Results posted
• Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)CompletedNCT02014051Phase 1Results posted
• Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension StudyCompletedNCT02002936Phase 1Results posted
• Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer PatientsCompletedNCT00856791Phase 2Results posted
• Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line TreatmentCompletedNCT04263090Phase 1/2
• Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCCCompletedNCT04177498Early Phase 1
• Rigosertib for RDEB-SCCCompletedNCT03786237Phase 1/2
• Study of SyB C-1101 in Patients With Myelodysplastic SyndromeCompletedNCT03495167Phase 1
• Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic SyndromeWithdrawnNCT02783547Phase 1
• Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMATerminatedNCT02562443Phase 3
• Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck CancerCompletedNCT02107235Phase 1
• Three Dosing Schedules of Oral Rigosertib in MDS PatientsWithdrawnNCT02075034Phase 1
• Metabolism and Excretion of [14C]-Rigosertib After Infusion to VolunteersCompletedNCT02030639Phase 1
• Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or DecitabineCompletedNCT01928537Phase 3
• Phase II Part 2 Expansion of Oral Rigosertib in Combination With AzacitidineCompletedNCT01926587Phase 1/2
• Oral Rigosertib in Low Risk MDS Patients Refractory to ESAsCompletedNCT01904682Phase 2
• Oral Rigosertib for Squamous Cell CarcinomaCompletedNCT01807546Phase 2
• Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic SyndromeCompletedNCT01584531Phase 2
• Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced CancerCompletedNCT01538563Phase 1
• Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced CancerCompletedNCT01538537Phase 1
• Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic CancerCompletedNCT01360853Phase 3
• Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess BlastsCompletedNCT01241500Phase 3
• Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid TumorsCompletedNCT01168011Phase 1
• Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)CompletedNCT01167166Phase 1/2
• Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid TumorsCompletedNCT01165905Phase 1
• Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid TumorsCompletedNCT01125891Phase 1
• Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic SyndromeCompletedNCT01048619Phase 1
• Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High RiskCompletedNCT00906334Phase 2
• Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)WithdrawnNCT00867061Phase 1/2
• Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With HepatomaCompletedNCT00861783Phase 1
• A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid MalignanciesCompletedNCT00861510Phase 1
• Safety Study of ON 01910.Na in Combination With Irinotecan or OxaliplatinCompletedNCT00861328Phase 1
• Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AMLCompletedNCT00854945Phase 1/2
• Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)CompletedNCT00854646Phase 1
• Safety of ON 01910.Na in Patients With MyelodysplasiaCompletedNCT00533416Phase 1

← ON 01910 overview